A Phase 1 interventional study of LY3025876 and Placebo in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-01-24.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 68th largest by enrollment, is one of 18 that started in 2013, is one of 25 in phase 1, and was the 78th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 21 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 18 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 156th largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2013, is one of 76 in phase 1, and was the 100th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
This study will also evaluate how much of the study drug enters the blood stream and how long it takes for the body to remove the study drug. Information about any side effects that may occur will also be collected. Participants will continue their usual diet and exercise program and may remain on their physician-prescribed dose of metformin.
Each part of the study is expected to last 10 to 12 weeks on average, not including screening. Participants may only enroll in one part.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: 0.5 milligram (mg), 1.5 mg, 5 mg, and 15 mg of LY3025876 administered as once daily (QD) subcutaneous (SQ) injections for up to 28 days.
Drug: LY3025876
Part B: Placebo matching LY3025876 administered as QD SQ injections for up to 28 days
Drug: Placebo
Part B: 5.0 mg of LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
Drug: LY3025876 · Drug: Liraglutide
Part B: Placebo doses matching LY3025876 and 1.8 mg liraglutide administered as separate QD SQ injections for up to 28 days, after titration of liraglutide over 2 weeks.
Drug: Placebo · Drug: Liraglutide
Administered SQ
Administered SQ
Administered SQ
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
Time frame: Predose on Day 1 up to Day 56 in each Part
Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC[0-24]) of LY3025876
AUC(0-24) of individual participants was calculated by equation Area Under Concentration (AUC)=Dose/CL, where the clearance (CL) was estimated using a population PK model.
Time frame: Predose and 0.5 hour(hr), 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 12 hr, and 24 hr Postdose
PK: Maximum Concentration (Cmax) of LY3025876
Time frame: Days 1 and 28: Predose and 0.5 hr, 1 hr, 2 hr, 3 hr, 4 hr, 6 hr, 8 hr, 10 hr, 12 hr, and 24 hr Postdose
Part A and Part B: Immunogenicity: The Number of Participants With Anti-LY3025876 Antibodies
Time frame: Predose on Day 7, 14, 28, 56, and 180
Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose
Least Squares Mean (LS) Mean change from baseline in fasting glucose was modeled using Mixed Effect Model Repeat Measurement (MMRM) analysis with fixed effects of baseline, treatment, day, treatment\*day interaction, and participant as a random effect.
Time frame: Baseline, Day 28
| Milestone | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Lirgalutide |
|---|---|---|---|---|---|---|---|
| Started | 11 | 15 | 8 | 9 | 10 | 9 | 10 |
| Completed | 11 | 8 | 7 | 9 | 7 | 8 | 8 |
| Not completed | 0 | 7 | 1 | 0 | 3 | 1 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Sponsor decision | 0 | 6 | 0 | 0 | 0 | 0 | 1 |
A summary of other non-serious adverse events and all serious adverse events, regardless of causality, is located in the Reported Adverse Events Section.
| participants | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide |
|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AUC(0-24) of individual participants was calculated by equation Area Under Concentration (AUC)=Dose/CL, where the clearance (CL) was estimated using a population PK model.
| nanograms*hour/milliliter (ng*hr/mL) | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | LY3025876 + Liraglutide |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to 24 Hours (AUC[0-24]) of LY3025876 | 51.5 ± 61.1 | 207 ± 51.2 | 622 ± 42.3 | 1930 ± 32.4 | 525 ± 37.8 |
| nanogram/milliliter (ng/mL) | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | 5.0 mg LY3025876 + Liraglutide |
|---|---|---|---|---|---|
| Day 1 | 3.90 ± 33.7 | 17.5 ± 43.7 | 45.1 ± 39.2 | 126 ± 44.3 | 40.3 ± 48.3 |
| Day 28 | 4.87 ± 85.7 | 14.2 ± 46.1 | 51.9 ± 31.3 | 185 ± 26.8 | 44.8 ± 53.8 |
| Participants | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide |
|---|---|---|---|---|---|---|---|
| Positive Antibodies Day 7 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Positive Antibodies Day 14 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Positive Antibodies Day 28 | 0 | 1 | 2 | 2 | 6 | 0 | 1 |
| Positive Antibodies Day 56 | 0 | 1 | 4 | 2 | 6 | 0 | 1 |
| Positive Antibodies Day 180 | 0 | 0 | 0 | 1 | 4 | 0 | 0 |
Least Squares Mean (LS) Mean change from baseline in fasting glucose was modeled using Mixed Effect Model Repeat Measurement (MMRM) analysis with fixed effects of baseline, treatment, day, treatment\*day interaction, and participant as a random effect.
| milligram/deciliter (mg/dL) | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo Part B | 5.0 mg LY3025876 + Liraglutide |
|---|---|---|---|---|---|---|---|
| Pharmacodynamics (PD): Change From Baseline to Day 28 in Fasting Glucose | 3.52 ± 8.41 | 18.08 ± 10.02 | 0.12 ± 9.92 | -14.50 ± 9.33 | 22.96 ± 11.51 | 11.72 ± 5.94 | 6.32 ± 5.64 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Part A | — | 0/11 (0%) | 5/11 (45.5%) |
| 0.5 mg LY3025876 | — | 0/15 (0%) | 7/15 (46.7%) |
| 1.5 mg LY3025876 | — | 0/8 (0%) | 8/8 (100%) |
| 5.0 mg LY3025876 | — | 0/9 (0%) | 9/9 (100%) |
| 15 mg LY3025876 | — | 0/10 (0%) | 10/10 (100%) |
| Placebo Part B | — | 0/9 (0%) | 9/9 (100%) |
| Placebo + Liraglutide | — | 0/10 (0%) | 9/10 (90%) |
| Event | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo Part B | Placebo + Liraglutide |
|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/11 | 1/15 | 1/8 | 1/9 | 9/10 | 0/9 | 3/10 |
| Frequent bowel movementsGastrointestinal disorders | 1/11 | 0/15 | 2/8 | 6/9 | 0/10 | 0/9 | 1/10 |
| Decreased appetiteMetabolism and nutrition disorders | 0/11 | 1/15 | 1/8 | 0/9 | 0/10 | 4/9 | 5/10 |
| NauseaGastrointestinal disorders | 0/11 | 0/15 | 1/8 | 2/9 | 3/10 | 4/9 | 4/10 |
| Injection site haemorrhageGeneral disorders | 1/11 | 0/15 | 0/8 | 0/9 | 0/10 | 4/9 | 1/10 |
| Early satietyGeneral disorders | 0/11 | 0/15 | 0/8 | 0/9 | 1/10 | 2/9 | 4/10 |
| Injection site erythemaGeneral disorders | 0/11 | 0/15 | 0/8 | 0/9 | 4/10 | 2/9 | 2/10 |
| Injection site pruritusGeneral disorders | 0/11 | 1/15 | 2/8 | 0/9 | 4/10 | 1/9 | 1/10 |
| Injection site rashGeneral disorders | 0/11 | 0/15 | 0/8 | 0/9 | 1/10 | 0/9 | 4/10 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/11 | 0/15 | 3/8 | 0/9 | 0/10 | 0/9 | 1/10 |
| Age, Continuous(years) | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide | Total |
|---|---|---|---|---|---|---|---|---|
| Age Part A | 53.4 ± 9.6 | 55.8 ± 7.6 | 53.3 ± 7.2 | 61.9 ± 5.5 | 55.3 ± 6.8 | NA ± NA | NA ± NA | 55.8 ± 7.8 |
| Age Part B | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 53.2 ± 8.9 | 54.4 ± 5.5 | 53.8 ± 7.1 |
| Sex: Female, Male(Participants) | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 4 | 5 | 4 | 2 | 2 | 2 | 3 | 22 |
| Male | 7 | 10 | 4 | 7 | 8 | 7 | 7 | 50 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 13 | 7 | 6 | 6 | 6 | 3 | 51 |
| Not Hispanic or Latino | 1 | 2 | 1 | 3 | 4 | 3 | 7 | 21 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 1 | 0 | 1 | 4 | 8 |
| White | 11 | 13 | 8 | 7 | 10 | 8 | 5 | 62 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 11 | 15 | 8 | 9 | 10 | 9 | 10 | 72 |
| Glycosylated Hemoglobin (HbA1c)(percent of HbA1c) | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide | Total |
|---|---|---|---|---|---|---|---|---|
| HbA1c Part A | 8.64 ± 0.65 | 8.39 ± 0.93 | 8.43 ± 0.88 | 8.94 ± 1.19 | 8.67 ± 0.92 | NA ± NA | NA ± NA | 8.59 ± 0.91 |
| HbA1c Part B | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 8.56 ± 0.77 | 8.05 ± 0.86 | 8.29 ± 0.84 |
| Fasting Serum Glucose (FSG)(milligram/deciliter (mg/dL)) | Placebo Part A | 0.5 mg LY3025876 | 1.5 mg LY3025876 | 5.0 mg LY3025876 | 15 mg LY3025876 | Placebo + Liraglutide | 5.0 mg LY3025876 + Liraglutide | Total |
|---|---|---|---|---|---|---|---|---|
| FSG Part A | 164.43 ± 31.59 | 148.08 ± 19.14 | 181.27 ± 47.84 | 175.74 ± 75.99 | 145.66 ± 23.22 | NA ± NA | NA ± NA | 161.63 ± 42.87 |
| FSG Part B | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 159.73 ± 36.54 | 152.22 ± 26.62 | 155.78 ± 31.02 |
The record gives a start of Jun 2013, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2019, 4 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide